Stockreport

LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

LAVA Therapeutics N.V. - Ordinary Shares  (LVTX) 
PDF Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty antic [Read more]